التفاصيل البيبلوغرافية
| العنوان: |
Selective IgA Deficiency and Blood Component Transfusion: In Search of the Lost Evidence. |
| المؤلفون: |
Solves, Pilar1,2 (AUTHOR) bataller_anaalf@gva.es, Bataller, Ana1 (AUTHOR) galvez_anarui@gva.es, Gálvez, Ana Belén1 (AUTHOR) asensi_ped@gva.es, Asensi Cantó, Pedro1 (AUTHOR) santiago_marbal@gva.es, Santiago, Marta1,2 (AUTHOR) gomez_ine@gva.es, Moreno, María José3 (AUTHOR) moreno_marjos@gva.es, Gómez-Seguí, Inés1,2 (AUTHOR) delarubia_jav@gva.es, de la Rubia, Javier1,2,4 (AUTHOR) |
| المصدر: |
Hemato. Jun2024, Vol. 5 Issue 2, p109-114. 6p. |
| مستخلص: |
Background: Selective IgA deficiency (IgA-D) has been historically considered a high-risk entity for developing allergic/anaphylactic reactions after blood transfusion (AATRs). However, it has been suggested that the IgA-D-related anaphylactic transfusion reaction is not evidence-based. Methods: We conducted three different approaches to collect evidence about epidemiology, AATRs, and transfusion management of patients with IgA-D at La Fe University Hospital. Firstly, we analysed the prevalence of IgA-D in a population of patients diagnosed with acute leukaemia, The second approach consisted of collecting transfusion data from IgA-D patients. Finally, we reviewed the IgA levels of patients recorded in the hemovigilance system suffering an AATR. Results: IgA-D prevalence was 1 in 334 patients. At least one blood component was transfused to 23 patients diagnosed with IgA-D. Plasma was transfused to eight IgA-D patients, while six patients received red blood cells, platelets, and plasma. No adverse reactions were reported in any patient. AATRs occurred in 325 men and 264 women with a median age of 52 years. Severe reactions occurred in 56 patients (1/14,520 components). Mean IgA levels were 215 mg/dL (4–5570) for mild reactions and 214 mg/dL (14–824) for severe reactions (p = ns). Washed platelets were administered to two patients who developed severe and repeated AATRs. Both had normal IgA levels. Conclusions: Since the AATRs related to IgA-D are extremely low, as reported in current hemovigilance systems, IgA-D should not be considered a high-risk entity to develop AATRs. On the contrary, our findings support standard transfusion management of IgA-D patients. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
